Showing results (681-690 of 1,892) with videos related to

Sort By:
Pageof 190
Immunotherapy|May 29, 2025
Biology-driven therapies of CAR T immune effector cell-associated neurotoxicity syndromeSophie Giesler, Francesca Biavasco, Tobias Wertheimer, et al.
Immunotherapy|November 4, 2025
Chimeric antigen receptor natural killer (CAR-NK) cells: from preclinical promise to clinical reality in cancer immunotherapyHunter Cassidy Cochran, Kevin Ashkan Ghobadi, Armin Ghobadi
Immunotherapy|July 7, 2025
Rescued with T and B lymphocytes depletion therapy for immune checkpoint inhibitor-associated transplant rejectionSiqi Qiu, Zhipeng Zong, Kang He
Immunotherapy|July 8, 2025
IgE-mediated anaphylaxis induced by pembrolizumabRomane Legroux, Jeanne-Marie Perotin, Gabrielle Wintrebert, et al.
Immunotherapy|April 2, 2025
Late-onset recurrent immune checkpoint inhibitor-related pneumonitis after cessation of pembrolizumab: a case reportBahadır Köylü, Cevat İlteriş Kıkılı, Öner Dikensoy, et al.
Immunotherapy|May 12, 2025
Oncolytic reovirus enhances the effect of CEA immunotherapy when combined with PD1-PDL1 inhibitor in a colorectal cancer modelAtefeh Yari, Seyed Younes Hosseini, Sanaz Asiyabi, et al.
Immunotherapy|May 8, 2025
Arthralgia in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysisYoshito Nishimura, Jonathan Estaris, Mako Koseki, et al.
Immunotherapy|August 9, 2025
Pitfalls and strategies of CAR-T therapy in solid tumors and implications for chordoma treatmentM Qi, G Cattaneo, C Camillo, et al.
Immunotherapy|August 11, 2025
Evaluating rilzabrutinib in the treatment of immune thrombocytopeniaDavid J Kuter, Waleed Ghanima
Immunotherapy|October 17, 2025
How should we choose optimal salvage treatments following BCMA-directed CAR T-cell therapy?Arvind Suresh, Darren Pan, Jodi Lipof, et al.
Pageof 190